Overall Perfomance for "Lion Stock Alerts"
The following three charts can be used by potential investors to gauge the performance of "Lion Stock Alerts":
1 out of 10 campaigns closed down on first day
4 out of 10 campaigns closed up on first day
5 out of 10 campaigns had no net effect
ATNM Promotional Newsletter
The following is a newsletter released by "Lion Stock Alerts" promoting Actinium Pharmaceuticals, Inc.
Don't Want Anymore Emails
We wanted to briefly update our newest alert, ATNM.
Today, ATNM announced breaking news that could be an additional growth catalyst for the company.
Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy
Here are the highlights from this press release
CAR T-cell therapy manufacturing commenced with Iomab-ACT conditioning and patient treatment scheduled for early Q22021
Clinical proof-of-concept data expected in 2H2021 from first of its kind trial funded by NIH STTR grant
As the company explained in the announcement
NEW YORK, March 24, 2021 PRNewswire -- Actinium Pharmaceuticals, Inc. NYSE AMERICAN ATNM Actinium or the Company today announced that its collaborator, Memorial Sloan Kettering Cancer Center MSK, has commenced patient enrollment in the Phase 1 study evaluating Iomab-ACT for targeted conditioning prior to treatment with MSK's CD19 targeted CAR T-cell 19-28z. Iomab-ACT is a low dose version of Actinium's Phase 3 drug candidate Iomab-B, a CD45 targeting antibody radiation conjugate ARC. Actinium and MSK were jointly awarded National Institutes of Health Small Business Technology Transfer grant funding for this first ever trial to evaluate ARC-based targeted conditioning prior to CAR-T therapy.
Here are some of the companys comments from this press release
Dr. Dale Ludwig, Actinium's Chief Scientific and Technology Officer, said MSK's 19-28z CAR T-cell therapy has produced high response rates in patients with relapsed or refractory B-ALL who have previously undergone several lines of standard therapy. However, toxicities such as cytokine release syndrome and neurologic toxicity, as well as durability of response, remain a significant challenge. The ARC technology Iomab-ACT employs enables the delivery of targeted radiation that selective and specifically targets immune cells including those implicated in the CAR-T-associated toxicities of neurotoxicity and cytokine release syndrome. We are eager to begin treating patients in this first of its kind pilot study to explore the potential of Iomab-ACT targeted lymphodepletion to modulate the immune system and improve the safety profile of CAR T-cell therapy. We are hopeful this technology may ultimately enhance our ability to deliver CAR T-cell therapies more safely. Positive results from pilot study could have a meaningful impact on the way we condition patients for CAR-T and other adoptive cell therapies, which have transformed the treatment of patients with blood cancers.
Sandesh Seth, Actinium's Chairman and CEO, said This is a major milestone for Actinium and one we are very excited by. Adoptive cell therapies like CAR-T and gene therapies have emerged as some of the most promising areas in medicine and hold tremendous promise for patients, many of whom have limited or no treatment options remaining.
This promise has led to a large and growing field of therapies where we intend to establish Iomab-ACT as the universal solution for targeted, non-chemotherapy conditioning, that harnesses the power of radiation.
With Iomab-B nearing complete enrollment in the Phase 3 SIERRA trial for bone marrow transplant conditioning, starting to treat patients in this Iomab-ACT trial for CAR-T conditioning could not come at a better time. We look forward to continuing to build out our strategic business unit in targeted conditioning to best serve patients seeking potentially curative bone marrow transplant, adoptive cell therapy and gene therapy to improve patient access and outcomes.
We are continuing to monitor this opportunity.
Sources , , , , , , , , , , , , , ,
Note We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
You should read and understand this disclaimer in its entirety before joining the website or emailblog list of LionStockAlerts.com the Publisher. The information collectively the Advertisement disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, andor losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission the SEC at www.sec.gov the Financial Industry Regulatory Authority the FINRA at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.govconsumercyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial andor legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 32321 for the distribution of this advertisement about ATNM dated 32421. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 12420 for the distribution of a prior advertisement about ATNM. Previously, owners and operators of the Publisher have been compensated fifteen thousand dollars by bank wire transfer on 102920 for the distribution of a prior advertisement about ATNM. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 101920 for the distribution of a prior advertisement about ATNM. Prior to this period, at the time of publication, we disclosed our compensation for the distribution of advertisements about ATNM. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
www.LionStockAlerts.comDisclaimer and www.LionStockAlerts.comPrivacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of 1 a client company, 2 the party issuing or preparing the information for the company, or 3 other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated reportrelease or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.
Our records indicate that . requested and confirmed to be added to LionStockAlerts.com on July 23, 2019.
6020 Bent Pine Drive
Orlando FL 32828